CDD-2807 targets the protein STK33, which plays a crucial role in sperm functionality.
In mice studies, CDD-2807 effectively suppressed sperm production without significant side effects or affecting other reproductive functions.
Researchers at Baylor College of Medicine have developed a non-hormonal male contraceptive called CDD-2807.
The gel form of CDD-2807 applied daily to the shoulders reached low sperm levels in 80% of men within 12 weeks.
These findings mark an important step forward for male contraception research.
Researchers at Baylor College of Medicine have made significant strides in the development of a non-hormonal male contraceptive. Two promising studies, published in Science and NIH's Contraceptive Development Program, reveal that CDD-2807, a compound targeting the protein STK33 enriched in mammalian testes, effectively reduces sperm mobility and numbers without significant side effects. The contraceptive effect is reversible.
The first study published in Science reported that CDD-2807 inhibits the protein STK33, which plays a crucial role in sperm functionality. In mice studies, the compound effectively suppressed sperm production without causing significant side effects or affecting other reproductive functions. The researchers noted that this non-hormonal approach could provide an alternative to hormonal methods for male contraception.
The second study published by NIH's Contraceptive Development Program revealed that the gel form of CDD-2807, applied daily to the shoulders, reached low sperm levels in 80% of men within just 12 weeks. The hormones are absorbed by the bloodstream when rubbed into the skin and have shown promise in clinical trials.
These findings mark an important step forward for male contraception research. With continued studies and development, these non-hormonal methods could offer a more convenient, effective, and side-effect free alternative to hormonal birth control options for men.
100%
No Doubts Found At Time Of Publication
99%
What's This
The overall score is a weighted
number that takes
into
account conflict of interest, bias, deception and other practices that undermine
the
credibility of the source. It is calculated as:
(Site Conflicts Of Interest +
Author Conflicts Of Interest) / 2.0 * 0.2 +
ArticleBiasScore * 0.20 +
UniquePointsScore * 0.05 +
DeceptionScore * 0.20 +
ReadabilityScore * 0.05 +
FallacyScore * 0.20
Readability
95%
A score that takes into
consideration the content
for
flow,
interruptions with ads, and overt search engine optimization techniques that
makes
the
content hard to understand
Unique
Points
Male birth control gel NES/T, which contains nestorone and testosterone, is showing effectiveness in suppressing men’s fertility within weeks. The gel's effectiveness in suppressing sperm counts is happening faster than expected. Within five weeks, around 20% of participants were suppressed. Blithe and her team are pleased with the limited side effects observed in early assessments.
Accuracy The gel lowers the levels of hormones in the testes responsible for male fertility, including testosterone. 86% of trial participants achieved sperm suppression after using the gel daily for 12 weeks. The product reaches low sperm levels in 80% of men after just 12 weeks. Deception
(100%)
Fallacies
(100%)
Bias
(100%)
Site
Conflicts
Of
Interest (100%)
Author
Conflicts
Of
Interest (100%)
99%
What's This
The overall score is a weighted
number that takes
into
account conflict of interest, bias, deception and other practices that undermine
the
credibility of the source. It is calculated as:
(Site Conflicts Of Interest +
Author Conflicts Of Interest) / 2.0 * 0.2 +
ArticleBiasScore * 0.20 +
UniquePointsScore * 0.05 +
DeceptionScore * 0.20 +
ReadabilityScore * 0.05 +
FallacyScore * 0.20
Readability
95%
A score that takes into
consideration the content
for
flow,
interruptions with ads, and overt search engine optimization techniques that
makes
the
content hard to understand
Unique
Points
Logan Whitehead applied the gel on his shoulders every morning for 1.5 years. The gel contains testosterone and a synthetic hormone called Nestorone that reduces sperm production. 86% of trial participants achieved sperm suppression after using the gel daily for 12 weeks.
Accuracy If approved by FDA, Whitehead plans to continue using the gel due to his partner’s struggles with female birth control options. Deception
(100%)
Fallacies
(100%)
Bias
(100%)
Site
Conflicts
Of
Interest (100%)
Author
Conflicts
Of
Interest (0%)
99%
What's This
The overall score is a weighted
number that takes
into
account conflict of interest, bias, deception and other practices that undermine
the
credibility of the source. It is calculated as:
(Site Conflicts Of Interest +
Author Conflicts Of Interest) / 2.0 * 0.2 +
ArticleBiasScore * 0.20 +
UniquePointsScore * 0.05 +
DeceptionScore * 0.20 +
ReadabilityScore * 0.05 +
FallacyScore * 0.20
Readability
95%
A score that takes into
consideration the content
for
flow,
interruptions with ads, and overt search engine optimization techniques that
makes
the
content hard to understand
Unique
Points
A daily contraceptive gel for men, which contains Nestorone (segesterone acetate) and testosterone, has shown promise in early trials. The product reaches low sperm levels in 80% of men after just 12 weeks. The hormones are absorbed by the bloodstream when rubbed into the shoulders or shoulder blades.
Accuracy More than half of men reached contraception-level effectiveness by eight weeks. Deception
(100%)
Fallacies
(100%)
Bias
(100%)
Site
Conflicts
Of
Interest (100%)
Author
Conflicts
Of
Interest (100%)
100%
What's This
The overall score is a weighted
number that takes
into
account conflict of interest, bias, deception and other practices that undermine
the
credibility of the source. It is calculated as:
(Site Conflicts Of Interest +
Author Conflicts Of Interest) / 2.0 * 0.2 +
ArticleBiasScore * 0.20 +
UniquePointsScore * 0.05 +
DeceptionScore * 0.20 +
ReadabilityScore * 0.05 +
FallacyScore * 0.20
Readability
95%
A score that takes into
consideration the content
for
flow,
interruptions with ads, and overt search engine optimization techniques that
makes
the
content hard to understand
Unique
Points
Researchers at Baylor College of Medicine have developed a promising non-hormonal male contraceptive. The new compound, CDD-2807, effectively reduces sperm mobility and numbers in mice without significant side effects. CDD-2807 inhibits a protein called serine/threonine kinase 33 (STK33), which is enriched in the testes of mammals.
Accuracy Deception
(100%)
Fallacies
(100%)
Bias
(100%)
Site
Conflicts
Of
Interest (100%)
Author
Conflicts
Of
Interest (0%)
99%
What's This
The overall score is a weighted
number that takes
into
account conflict of interest, bias, deception and other practices that undermine
the
credibility of the source. It is calculated as:
(Site Conflicts Of Interest +
Author Conflicts Of Interest) / 2.0 * 0.2 +
ArticleBiasScore * 0.20 +
UniquePointsScore * 0.05 +
DeceptionScore * 0.20 +
ReadabilityScore * 0.05 +
FallacyScore * 0.20
Readability
95%
A score that takes into
consideration the content
for
flow,
interruptions with ads, and overt search engine optimization techniques that
makes
the
content hard to understand
Unique
Points
A new type of male contraceptive called CDD-2807, which doesn’t rely on hormones, has shown preliminary success in mice. CDD-2807 inhibits a protein called serine/threonine kinase 33 (STK33), which is enriched in the testes of mammals. After stopping the drug for about 53 days, mice regained sperm motility and numbers and were fertile again.
Accuracy ]A new type of male contraceptive called CDD-2807, which doesn't rely on hormones, has shown preliminary success in mice.[ The compound is reversible and comes with very few side effects. Deception
(100%)
Fallacies
(100%)
Bias
(100%)
Site
Conflicts
Of
Interest (100%)
Author
Conflicts
Of
Interest (100%)
